2. Academic Validation
  3. Design and synthesis of novel 7-aminosubstituted pyrido[2,3-b]pyrazines exhibiting anti-breast cancer activity

Design and synthesis of novel 7-aminosubstituted pyrido[2,3-b]pyrazines exhibiting anti-breast cancer activity

  • Eur J Med Chem. 2017 Jan 27:126:954-968. doi: 10.1016/j.ejmech.2016.12.025.
Orestis Argyros 1,  Nikolaos Lougiakis 2,  Eva Kouvari 3,  Alexandra Papafotika 4,  Catherine P Raptopoulou 5,  Vassilis Psycharis 6,  Savvas Christoforidis 7,  Nicole Pouli 8,  Panagiotis Marakos 9,  Constantin Tamvakopoulos 10
Affiliations

Affiliations

  • 1 Division of Pharmacology-Pharmacotechnology, Biomedical Research Foundation Academy of Athens (BRFAA), Athens, 11527, Greece. Electronic address: ore_argyros@yahoo.com.
  • 2 School of Health Sciences, Department of Pharmacy, Division of Pharmaceutical Chemistry, National and Kapodistrian University of Athens, Panepistimiopolis, Zografou, Athens, 15771, Greece. Electronic address: nlougiak@pharm.uoa.gr.
  • 3 Division of Pharmacology-Pharmacotechnology, Biomedical Research Foundation Academy of Athens (BRFAA), Athens, 11527, Greece. Electronic address: eva_kouvari@yahoo.gr.
  • 4 Institute of Molecular Biology and Biotechnology, Department of Biomedical Research, Foundation for Research and Technology Hellas, 45110, Ioannina, Greece; Laboratory of Biological Chemistry, Department of Medicine, School of Health Sciences, University of Ioannina, 45110, Ioannina, Greece. Electronic address: apapafot@cc.uoi.gr.
  • 5 Institute of Nanoscience and Nanotechnology, N.C.S.R "Demokritos", Athens, 15310, Greece. Electronic address: c.raptopoulou@inn.demokritos.gr.
  • 6 Institute of Nanoscience and Nanotechnology, N.C.S.R "Demokritos", Athens, 15310, Greece. Electronic address: v.psycharis@inn.demokritos.gr.
  • 7 Institute of Molecular Biology and Biotechnology, Department of Biomedical Research, Foundation for Research and Technology Hellas, 45110, Ioannina, Greece; Laboratory of Biological Chemistry, Department of Medicine, School of Health Sciences, University of Ioannina, 45110, Ioannina, Greece. Electronic address: schristo@uoi.gr.
  • 8 School of Health Sciences, Department of Pharmacy, Division of Pharmaceutical Chemistry, National and Kapodistrian University of Athens, Panepistimiopolis, Zografou, Athens, 15771, Greece. Electronic address: pouli@pharm.uoa.gr.
  • 9 School of Health Sciences, Department of Pharmacy, Division of Pharmaceutical Chemistry, National and Kapodistrian University of Athens, Panepistimiopolis, Zografou, Athens, 15771, Greece. Electronic address: marakos@pharm.uoa.gr.
  • 10 Division of Pharmacology-Pharmacotechnology, Biomedical Research Foundation Academy of Athens (BRFAA), Athens, 11527, Greece. Electronic address: ctamvakop@bioacademy.gr.
PMID: 28006668 DOI: 10.1016/j.ejmech.2016.12.025
Abstract

Breast Cancer (BrCa) remains an unmet medical need despite the revolutionary development of antibody treatments and protein kinase inhibitors. In the current study, a series of novel substituted pyridopyrazine derivatives have been rationally designed and evaluated as multi-kinase inhibitors in the PI3K pathway. The target compounds were prepared from 6-amino-2-picoline, which upon nitration and selective reduction was converted to suitably substituted 6-methyl-7-aminopyrido[2,3-b]pyrazines. Suitable manipulation of the former amines provided the designed analogues, which were then assessed in vitro against several BrCa cell lines using the MTT cytotoxicity assay. The most potent compounds underwent evaluation in a broad spectrum of protein kinases, while their pharmacokinetic parameters were measured by LC-MS/MS. In vivo evaluation of a hit compound (14a) was performed in a HER2 amplified BrCa xenograft model (HCC1954) and efficacy was determined using Western blot based phosphokinase assays and immunohistochemistry. This derivative showed low micromolar cytotoxic potency in all BrCa cell lines, a mild inhibition of the PI3Kα wild type and H1047R mutated Enzyme and excellent pharmacokinetic parameters following oral and intraperitoneal administration at the designed dose of 10 mg/kg, with absence of in vivo phenotypic toxicity. Interestingly, compound 14a inhibited the growth of xenografted tumors. Analysis of excised tumors from the treated Animals showed a significantly reduced population of Ki-67 positive cells, as well as downregulated levels of phosphorylated Akt, ERK1/2 and Src compared to vehicle treated Animals. Finally, the specificity of 14a was assessed in a panel of 31 kinases where a mild, but direct, inhibition of the MET receptor tyrosine kinase was observed.

Keywords

Breast cancer; In vivo activity; Met translational medicine; PI3K; Pharmacokinetic parameters; Pyridopyrazine.

Figures
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z